Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

April 2019

Volume 19Issue 2p89-156, e271-e398

Select all

Download started.
Ok

Please select at least one article in order to proceed.

A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology

Arti Hurria,
Enrique Soto-Perez-de-Celis,
Suzette Blanchard,
...
Andrea Rubalcava,
Rachel Morrison,
Joanne E. Mortimer

Published online: October 15, 2018

p89-96

Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study

Kimberly L. Blackwell,
Khalil Zaman,
Shukui Qin,
...
Richard Bryce,
Lori J. Goldstein
on behalf of the 202 Study Group

Published online: December 19, 2018

p97-104.e4

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

Vanesa Ortega,
Antonio Antón,
Isabel Garau,
...
José Manuel Pérez-García,
Javier Cortés,
Antonio Llombart-Cussac

Published online: December 19, 2018

p105-112

Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome

Vassiliki Kotoula,
Kalliopi Tsakiri,
Georgia-Angeliki Koliou,
...
Eleni Res,
Dimitrios Pectasides,
George Fountzilas

Published online: November 05, 2018

p113-125.e4

21-Gene Recurrence Score Testing in HER2-positive Patients

Ariella M. Altman,
Schelomo Marmor,
Todd M. Tuttle,
Jane Yuet Ching Hui

Published online: November 27, 2018

p126-130

Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast

Semir Vranic,
Juan Palazzo,
Souzan Sanati,
...
Joanne Xiu,
Jeffrey Swensen,
Zoran Gatalica

Published online: September 05, 2018

p131-136

Open Access

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Sara Gagno,
Mario Rosario D’Andrea,
Mauro Mansutti,
...
Chiara Saggia,
Federico Innocenti,
Giuseppe Toffoli

Published online: November 23, 2018

p137-145.e4

Open Access

Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade

Heather A. Jacene,
Trisha Youn,
Pamela J. DiPiro,
...
Eren Yeh,
Beth Overmoyer
Dana-Farber Cancer Institute Inflammatory Breast Cancer Program

Published online: November 26, 2018

p146-155

Editorial Board

Published in issue: April 2019

A2-A6

April 2019

Original Studies

A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology

Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome

21-Gene Recurrence Score Testing in HER2-positive Patients

Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade

Available Exclusively Online at www.clinical-breast-cancer.com

Testosterone and Breast Cancer in Transmen: Case Reports, Review of the Literature, and Clinical Observation

Significance of Serum Survivin and -31G/C Gene Polymorphism in the Early Diagnosis of Breast Cancer in Egypt

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Impact of Baseline Cardiovascular Comorbidity on Outcomes in Women With Breast Cancer: A Real-world, Population-based Study

Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles

A Prospective Cohort Study on the Impact of Reflexology in Patients With Breast Cancer Using the MYCaW Scale

Implementation of a Multidisciplinary Model of Care for Women With Metastatic Breast Cancer: Challenges and Lessons Learned

Soy Foods Might Weaken the Sensitivity of Tamoxifen in Premenopausal Patients With Lumina A Subtype of Breast Cancer

Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy: A Propensity Score Analysis and Predictors of Care for Patients With Brain Metastases From Breast Cancer

Ultrasound-Guided Vacuum-Assisted Biopsy in Small Breast: A Cost-Saving Solution

Breast Reconstruction Actualized in Nipple-sparing Mastectomy and Direct-to-implant, Prepectoral Polyurethane Positioning: Early Experience and Preliminary Results

Comparison of Radioactive Seed Localized Excision and Wire Localized Excision of Breast Lesions: A Community Hospital’s Experience

The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China

A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care

8-Hydroxy-2’-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer

Role of Overweight, Obesity, and Comorbidities in the Prognosis of Patients With Breast Cancer With Brain Metastases

Frontmatter

Editorial Board

Table of Contents